Toutes les études
RecrutementPHASE1, PHASE2INTERVENTIONNEL

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

This study is looking into a new medicine called LTP001. It has two main parts. In the first part (Part A), healthy volunteers will take the medicine. This helps doctors learn if LTP001 is safe, how the body handles it, and if there are any side effects. In the second part (Part B), people who have a serious lung condition called Pulmonary Arterial Hypertension (PAH) will receive the medicine. The aim here is to see if LTP001 can help their condition and if it's safe for them. After that, there will be a phase to keep checking on their safety. The study involves both males and females aged 18 to 100 years.

En un coup d'œil

Statut
Recrutement
Phase
PHASE1, PHASE2
Sponsor
Novartis Pharmaceutiques
Objectif d'inscription
232
Démarrer
24 Oct 2024
Achèvement estimé
31 Déc 2028

De quoi parle cette étude ?

This study is designed to learn more about a new medication called LTP001. It's being tested in stages to make sure it's safe and to understand how it works in the body. Developing new medicines involves careful steps, and this study is an important part of that process.

The study has two parts. The first part, called Part A, will involve healthy volunteers. Healthy people taking part helps researchers understand how the medicine behaves in the body when there are no other health conditions. They'll be checking things like how much medicine gets into the blood, how long it stays there, and if there are any side effects. This step is really important for safety before the medicine is given to people who are unwell.

The second part, called Part B, will include individuals who have Pulmonary Arterial Hypertension (PAH). PAH is a serious condition that affects the blood vessels in the lungs. In this part of the study, researchers want to see if LTP001 can improve the condition of people with PAH and if it continues to be safe for them. Participants in Part B will already be receiving their usual PAH treatments, and LTP001 will be given in addition to these. The study also includes a safety follow-up period to keep an eye on participants after they've finished taking the study medicine.

Points clés

  • New medicine LTP001 is being studied for safety and how it works.
  • First part is for healthy volunteers, second part for people with PAH.
  • Compares LTP001 to a placebo (dummy medicine).
  • You'll have regular medical checks and tests if you take part.
  • Participation is voluntary; you can withdraw at any time.

Qui peut être éligible ?

This study is open to both men and women between the ages of 18 and 100.

For Part A, if you are a healthy adult, you might be able to join. However, you cannot have any major heart problems or other serious health issues that could affect how your body handles the medicine or put you at risk during the study. If you are female, you must not be able to have children (for example, if you've been through menopause or had a hysterectomy).

For Part B, you must have a confirmed diagnosis of PAH and be on stable doses of your usual PAH medicines. You'll need to be able to walk between 150 and 450 metres in 6 minutes. You cannot have any medical conditions that would put you at higher risk in the study. Women who could become pregnant must use very effective birth control. Men must agree to use a condom during sex while taking the study medicine and for a day after stopping it. You also can't have had a bad reaction to similar medicines before.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Are you between 18 and 100 years old?
  2. If you have PAH, are you on stable doses of your usual PAH medicines?
  3. Do you have any serious heart conditions or other major health problems?
  4. If you are female, can you become pregnant?
  5. If male and sexually active, are you willing to use a condom during the study?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you decide to take part, you will be given either the new medicine, LTP001, or a 'placebo'. A placebo looks like the real medicine but contains no active ingredients; this helps researchers compare the effects of the new medicine fairly. You won't know if you're getting the active medicine or the placebo.

You will have regular visits to the clinic for check-ups. These visits will involve various assessments, such as blood tests, heart checks (ECG), and physical examinations to make sure you're doing well and to see how the medicine is affecting your body. For those with PAH, your walking ability may also be assessed.

The total length of time you'll be involved in the study will vary depending on which part you join, but it will involve taking the study medication for a period, followed by regular check-ups. You will be told the exact duration before you agree to take part.

Risques et avantages potentiels

Taking part in a study like this could offer potential benefits, such as access to a new treatment that isn't widely available yet, which might help your condition if you have PAH. You'll also receive careful medical monitoring. However, there are also potential risks; you might experience side effects from the study medicine, or for those in Part B, the medicine might not help your PAH. The placebo also means you might not get the active treatment. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (87)

  • Arizona Pulmonary Specialists Ltd
    Code postal vérifié
    Scottsdale, États-Unis· Recrutement
  • UC Irvine Medical Center
    Code postal vérifié
    Orange, United States· Recrutement
  • Stanford Medical Center
    Code postal vérifié
    Stanford, United States· Recrutement
  • Univ Colorado Hospital
    Code postal vérifié
    Aurora, États-Unis· Recrutement
  • Central Florida Pulmonary Group
    Code postal vérifié
    Orlando, United States· Recrutement
  • University of South Florida
    Code postal vérifié
    Tampa, États-Unis· Recrutement
  • Emory University School of Medicine
    Code postal vérifié
    Atlanta, États-Unis· Recrutement
  • U of Kansas Medical Center
    Code postal vérifié
    Kansas City, États-Unis· Recrutement
  • Norton Infectious Diseases Specialists
    Code postal vérifié
    Louisville, United States· Recrutement
  • Centre Médical Tufts
    Code postal vérifié
    Boston, États-Unis· Recrutement
  • Lahey Hospital and Medical Center
    Code postal vérifié
    Burlington, United States· Recrutement
  • Sky Integrative Medical Center SKYCRNG PPDS
    Code postal vérifié
    Ridgeland, United States· Recrutement

Questions fréquentes

What is Pulmonary Arterial Hypertension (PAH)?

PAH is a serious condition where the blood vessels in your lungs become narrowed, making it harder for your heart to pump blood through them. This can cause symptoms like shortness of breath and tiredness.

Qu'est-ce qu'un 'placebo' ?

A placebo is a 'dummy' treatment that looks just like the real medicine but doesn't contain any active drug. Giving some people a placebo helps researchers fairly compare the new medicine's effects against doing nothing extra.

Will I know if I'm getting the actual medicine or a placebo?

No, during the study, neither you nor your study doctor will know if you are receiving the active medicine or the placebo. This helps prevent bias in the results.

Combien de temps durera l'étude ?

The total length of time you would be involved in the study will be explained in detail by the study team. It will include time taking the medicine and follow-up appointments.

Puis-je quitter l'étude à tout moment ?

Yes, you are free to leave the study at any point, for any reason, without it affecting your future medical care.

Comment en savoir plus

Novartis Pharmaceutiques

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Intéressé à participer ?

Inscrivez votre intérêt

Partagez vos coordonnées et l'équipe de recherche pour "A Study to Learn About the Treatment LTP001 in Healthy Parti… vous contactera si vous êtes éligible. Consultez toujours votre médecin avant d'accepter de participer.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.